A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.
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Ethics oversight
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Sample sizes are based on previous published data using pathophysiological techniques of echocardiography, hemodynamics, etc. All approaches are documented.
No data are excluded.
All experiments were done using technical and biological replicates, and data were confirmed using a variety of genetic and pharmacologic approaches.
All animals were randomized in the studies.
All data evaluations were done blinded by the analyzer.
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